Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Children, adolescents and adults with attention-deficit/hyperactivity disorder (ADHD) experience functional impairment and poor health-related quality of life (HRQoL) in addition to symptoms of inattention/hyperactivity-impulsivity. To synthesize qualitatively the published evidence from randomized, double-blind, placebo-controlled trials of the effectiveness of pharmacotherapy on functional impairment or HRQoL in patients with ADHD, a systematic PubMed searching and screening strategy was designed to identify journal articles meeting pre-specified criteria. Post hoc analyses and meta-analyses were excluded. HRQoL outcomes, functional outcomes and the principal ADHD symptom-based outcome were extracted from included studies. An effect size of 0.5 versus placebo was used as a threshold for potential clinical relevance (unreported effect sizes were calculated when possible). Of 291 records screened, 35 articles describing 34 studies were included. HRQoL/functioning was usually self-rated in adults and proxy-rated in children/adolescents. Baseline data indicated substantial HRQoL deficits in children/adolescents. Placebo-adjusted effects of medication on ADHD symptoms, HRQoL and functioning, respectively, were statistically or nominally significant in 18/18, 10/12 and 7/9 studies in children/adolescents and 14/16, 9/11 and 9/10 studies in adults. Effect sizes were ≥0.5 versus placebo for symptoms, HRQoL and functioning, respectively, in 14/16, 7/9 and 4/8 studies in children/adolescents; and 6/12, 1/6 and 1/8 studies in adults. Effect sizes were typically larger for stimulants than for non-stimulants, for symptoms than for HRQoL/functioning, and for children/adolescents than for adults. The efficacy of ADHD medication extends beyond symptom control and may help reduce the related but distinct functional impairments and HRQoL deficits in patients with ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
(1995) · Social Science & Medicine · doi:10.1016/0277-9536(95)00112-k · Cited by 7,643
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700 · cited 3×
“5 (an approximate indicator of minimum clinically important difference) [71] for ADHD symptom outcomes in at least one active treatment group were observed in all of these 16 studies except the long-term ATX withdrawal study [65] and the adjunctive GXR study [100].”
BackgroundMethodKessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · cited 1×
“It has become clear that ADHD has a negative impact on patients’ HRQoL and that this may be further exacerbated by, or may increase the risk of, other psychiatric conditions such as anxiety and depression [31, 34, 54, 93].”
BackgroundPolanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C., & Rohde, L. A. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyt261 · Cited by 1,822
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Medication for Attention Deficit–Hyperactivity Disorder and Criminality
Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203241 · Cited by 611
The quality of life of children with attention deficit/hyperactivity disorder: a systematic review
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., Santosh, P., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0046-3 · Cited by 516
Self-citationEfficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD
GREENHILL, L., KOLLINS, S., ABIKOFF, H., MCCRACKEN, J., RIDDLE, M., SWANSON, J., MCGOUGH, J., WIGAL, S., WIGAL, T., VITIELLO, B., et al. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000235077.32661.61 · Cited by 467 · cited 1×
“…[as appropriate]) c CHQ-PF50 concepts, CHIP-CE:PRF subdomains and BSFQ individual items were not included d Effect sizes could not be calculated for Greenhill et al. 2006 [50] e ATX doses of 0.5, 1.2 or 1.8 mg/kg/day; results shown as a range across the three doses f Publication does not specify…”
BackgroundInfluentialNewcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336
Adolescent quality of life, Part II: initial validation of a new instrument
PATRICK, D. L., EDWARDS, T. C., & TOPOLSKI, T. D. (2002) · Journal of Adolescence · doi:10.1006/jado.2002.0471 · Cited by 260
Stimulant ADHD medication and risk for substance abuse
Chang, Z., Lichtenstein, P., Halldner, L., D'Onofrio, B., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12164 · Cited by 225 · cited 1×
“Recent evidence from observational and registry studies indicates that pharmacological treatment of ADHD is associated with increased achievement and decreased absenteeism at school [16], a reduced risk of trauma-related emergency hospital visits [58], reduced risks of suicide and attempted suicide [28], and decreased…”
BackgroundStorebø, O. J., Krogh, H. B., Ramstad, E., Moreira-Maia, C. R., Holmskov, M., Skoog, M., Nilausen, T. D., Magnusson, F. L., Zwi, M., Gillies, D., et al. (2015) · BMJ · doi:10.1136/bmj.h5203 · Cited by 209
Medori, R., Ramos-Quiroga, J. A., Casas, M., Kooij, J. J. S., Niemelä, A., Trott, G.-E., Lee, E., & Buitelaar, J. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.008 · Cited by 186
Adler, L. A., Liebowitz, M., Kronenberger, W., Qiao, M., Rubin, R., Hollandbeck, M., Deldar, A., Schuh, K., & Durell, T. (2009) · Depression and Anxiety · doi:10.1002/da.20549 · Cited by 176 · cited 2×
“…0.31*** Durell et al. 2013 [40]d ATX 0.40*** 0.26** 0.23* 0.17NS 0.23* 0.27** Adler et al. 2009a [5]f ATX 0.47*** 0.21NS 0.22* 0.17NS 0.20NS 0.24* Adler et al. 2009b [6]d,g ATX 0.28** (AISRS) 0.27** 0.23* 0.15NS 0.19* 0.27** Lee et al. 2014 [55] ATX 0.99** 0.47NS 0.27NS 0.45NS 0.31NS 0.53NS…”
InfluentialNewcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200503000-00008 · Cited by 174 · cited 1×
“1 3 Articles excluded at full-text screening reported studies that: lacked a comparison of medication with placebo [20, 60, 87], lacked an eligible HRQoL or functional impairment outcome [23, 24, 26, 63, 74] or were post hoc analyses [62, 69].”
BackgroundChen, Q., Sjolander, A., Runeson, B., D'Onofrio, B. M., Lichtenstein, P., & Larsson, H. (2014) · BMJ · doi:10.1136/bmj.g3769 · Cited by 170 · cited 1×
“Recent evidence from observational and registry studies indicates that pharmacological treatment of ADHD is associated with increased achievement and decreased absenteeism at school [16], a reduced risk of trauma-related emergency hospital visits [58], reduced risks of suicide and attempted suicide [28], and decreased…”
BackgroundBarbaresi, W. J., Katusic, S. K., Colligan, R. C., Weaver, A. L., & Jacobsen, S. J. (2007) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3180cabc28 · Cited by 161
Brown, T. E., & Landgraf, J. M. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2200 · Cited by 160
Riley, A. W., Spiel, G., Coghill, D., Döpfner, M., Falissard, B., Lorenzo, M. J., Preuss, U., Ralston**, S. J., & ADORE Study Group* (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-1006-9 · Cited by 156
Self-citationAmphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Punja, S., Shamseer, L., Hartling, L., Urichuk, L., Vandermeer, B., Nikles, J., & Vohra, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009996.pub2 · Cited by 122 · cited 2×
“Randomized controlled trials of pharmacotherapies in children, adolescents and adults with ADHD have typically used a clinician-rated symptom scale as the primary efficacy outcome measure, and meta-analyses of these studies have confirmed that ADHD medications are very effective in relieving patients’ symptoms [33, 77…”
MethodResultFindling, R. L., Childress, A. C., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Squires, L. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.01.007 · Cited by 120 · cited 6×
“…Impairment Rating Scale-Parent * p < 0.05; ** p < 0.01; *** p < 0.001 (active treatment vs placebo) a Effect sizes could not be calculated for Findling et al. 2011 [45], the only study to use the Youth Quality of Life Instrument-Research Version b Effect sizes of active medication versus…”
BackgroundMethodInfluentialA randomized controlled trial of CBT therapy for adults with ADHD with and without medication
Weiss, M., Murray, C., Wasdell, M., Greenfield, B., Giles, L., & Hechtman, L. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-30 · Cited by 119 · cited 4×
“5 for both ADHD symptoms and HRQoL or functioning in six out of these 12 studies: three of ATX, two of OROS-MPH and one of metadoxine [25, 40, 59, 79, 82, 96].”
BackgroundResultInfluentialAbikoff, H. B., Vitiello, B., Riddle, M. A., Cunningham, C., Greenhill, L. L., Swanson, J. M., Chuang, S. Z., Davies, M., Kastelic, E., Wigal, S. B., et al. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0068 · Cited by 118
Methylphenidate and the risk of trauma
Man, K. K. C., Chan, E. W., Coghill, D., Douglas, I., Ip, P., Leung, L.-P., Tsui, M. S. H., Wong, W. H. S., & Wong, I. C. K. (2015) · Pediatrics · doi:10.1542/peds.2014-1738 · Cited by 108 · cited 1×
“Recent evidence from observational and registry studies indicates that pharmacological treatment of ADHD is associated with increased achievement and decreased absenteeism at school [16], a reduced risk of trauma-related emergency hospital visits [58], reduced risks of suicide and attempted suicide [28], and decreased…”
BackgroundSelf-citationNICE guideline: attention deficit hyperactivity disorder: Figure 1
Atkinson, M., & Hollis, C. (2010) · Archives of disease in childhood - Education & practice edition · doi:10.1136/adc.2009.175943 · Cited by 97 · cited 1×
“Guidelines recommend that drug therapy is used as part of a multimodal treatment plan, which should include psychoeducation or other non-pharmacological interventions such as parent training and cognitive behavioural therapy [13, 102].”
BackgroundFunctional Outcomes in the Treatment of Adults With ADHD
Adler, L. A., Spencer, T. J., Levine, L. R., Ramsey, J. L., Tamura, R., Kelsey, D., Ball, S. G., Allen, A. J., & Biederman, J. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707308490 · Cited by 93 · cited 3×
“a Parent version of CHQ assumed (not specified in article) [68] b DAS (patient), PSI (patient), PSCS (patient), FAM-III (patient) and APQ-Patient (patient) AAQoL Adult ADHD Quality of Life, ADHD attention-deficit/hyperactivity disorder, AIM-A ADHD Impact Module-Adult, APQ Alabama Parenting Questionnaire, APRS Academic…”
MethodSpencer, T. J., Adler, L. A., Weisler, R. H., & Youcha, S. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0911 · Cited by 79
Retz, W., Rösler, M., Ose, C., Scherag, A., Alm, B., Philipsen, A., Fischer, R., Ammer, R., & The Study Group (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.540257 · Cited by 79
Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL)
Matza, L. S., Johnston, J. A., Faries, D. E., Malley, K. G., & Brod, M. (2007) · Quality of Life Research · doi:10.1007/s11136-007-9254-9 · Cited by 69 · cited 3×
“1 3 Articles excluded at full-text screening reported studies that: lacked a comparison of medication with placebo [20, 60, 87], lacked an eligible HRQoL or functional impairment outcome [23, 24, 26, 63, 74] or were post hoc analyses [62, 69].”
BackgroundMethodDurell, T. M., Adler, L. A., Williams, D. W., Deldar, A., McGough, J. J., Glaser, P. E., Rubin, R. L., Pigott, T. A., Sarkis, E. H., & Fox, B. K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827d8a23 · Cited by 64
Adler, L. A., Dirks, B., Deas, P. F., Raychaudhuri, A., Dauphin, M. R., Lasser, R. A., & Weisler, R. H. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08144 · Cited by 62 · cited 12×
“Effect sizes were not calculable for the other two studies that used the AIM-A, but significant placebo-adjusted effects of MAS-XR3 (triple-bead mixed amphetamine salts extended release) were reported in all domains in one study [85] and of OROS-MPH in three to four domains, depending on dose, in the other [25].”
BackgroundInfluentialDell'Agnello, G., Maschietto, D., Bravaccio, C., Calamoneri, F., Masi, G., Curatolo, P., Besana, D., Mancini, F., Rossi, A., Poole, L., et al. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.07.008 · Cited by 54 · cited 12×
“Baseline CHIP-CE:PRF T-scores from five included studies (two of LDX and three of ATX) were strikingly consistent in indicating that children and adolescents with ADHD have substantially impoverished HRQoL before treatment, especially in the Achievement and Risk Avoidance domains [14, 15, 37, 42, 91].”
BackgroundMethodInfluentialSelf-citationTowards an ICF core set for ADHD: a worldwide expert survey on ability and disability
de Schipper, E., Mahdi, S., Coghill, D., de Vries, P. J., Gau, S. S.-F., Granlund, M., Holtmann, M., Karande, S., Levy, F., Almodayfer, O., et al. (2015) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-015-0778-1 · Cited by 48 · cited 1×
“It will be interesting to see whether recent work to develop a standardized nomenclature and toolkit to describe and code functional impairment in people with ADHD based on the World Health Organization’s International Classification of Functioning, Disability and Health will result in a more cohesive and structured a…”
BackgroundSelf-citationAdler, L. A., Dirks, B., Deas, P., Raychaudhuri, A., Dauphin, M., Saylor, K., & Weisler, R. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-253 · Cited by 45
Buitelaar, J. K., Wilens, T. E., Zhang, S., Ning, Y., & Feldman, P. D. (2009) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2008.01960.x · Cited by 41
Banaschewski, T., Johnson, M., Lecendreux, M., Zuddas, A., Adeyi, B., Hodgkins, P., Squires, L. A., & Coghill, D. R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0193-z · Cited by 41
Self-citationSpencer, T. J., Landgraf, J. M., Adler, L. A., Weisler, R. H., Anderson, C. S., & Youcha, S. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1112 · Cited by 39 · cited 6×
“Effect sizes were not calculable for the other two studies that used the AIM-A, but significant placebo-adjusted effects of MAS-XR3 (triple-bead mixed amphetamine salts extended release) were reported in all domains in one study [85] and of OROS-MPH in three to four domains, depending on dose, in the other [25].”
BackgroundResultInfluentialCasas, M., Rösler, M., Sandra Kooij, J. J., Ginsberg, Y., Ramos-Quiroga, J. A., Heger, S., Berwaerts, J., Dejonckheere, J., van der Vorst, E., & Schäuble, B. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.600333 · Cited by 38
Wilens, T. E., Hammerness, P., Martelon, M., Brodziak, K., Utzinger, L., & Wong, P. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05779pur · Cited by 30 · cited 18×
“87 for CHQ-PF50 Psychosocial summary score [low, medium and high dose, respectively]) [66, 99].”
BackgroundMethodInfluentialManos, M., Frazier, T. W., Landgraf, J. M., Weiss, M., & Hodgkins, P. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903388797 · Cited by 30
Cannon, M., Pelham, W. H., Sallee, F. R., Palumbo, D. R., Bukstein, O., & Daviss, W. B. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0008 · Cited by 29
Cited by
Attention-deficit/hyperactivity disorder
Faraone, S. V., Bellgrove, M. A., Brikell, I., Cortese, S., Hartman, C. A., Hollis, C., Newcorn, J. H., Philipsen, A., Polanczyk, G. V., Rubia, K., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00495-0 · Cited by 355
Pharmacologic Treatment of Attention Deficit–Hyperactivity Disorder
Cortese, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1917069 · Cited by 342
Treatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Self-citationRuiz-Goikoetxea, M., Cortese, S., Aznarez-Sanado, M., Magallón, S., Alvarez Zallo, N., Luis, E. O., de Castro-Manglano, P., Soutullo, C., & Arrondo, G. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.11.007 · Cited by 175
Self-citationAnnual Research Review: Perspectives on progress in ADHD science – from characterization to cause
Sonuga‐Barke, E. J. S., Becker, S. P., Bölte, S., Castellanos, F. X., Franke, B., Newcorn, J. H., Nigg, J. T., Rohde, L. A., & Simonoff, E. (2023) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13696 · Cited by 157
Metadata
- Authors
- Coghill, D. R., Banaschewski, T., Soutullo, C., Cottingham, M. G., & Zuddas, A.
- Venue
- European Child & Adolescent Psychiatry
- Published
- 2017-04-20
- Volume
- 26
- Issue
- 11
- Pages
- 1283-1307
- ISSN
- 1018-8827 (ISSN-L)
- 1435-165X
- OpenAlex
- W2605665656
- Cited by
- 122
- References
- 44
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.